Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO (brexanolone) Injection for Treatment of Postpartum Depression


Yeah hopefully sage 217 will be the price of normal SSRI’s or near enough to that, something everyone can easily get their hands on.


Indeed. The significant cost upfront for Brexanolone is that it has to be administered by a qualifying nurse for 60 hours straight in a hospital setting.

Further, if you’re employed, it’ll be very likely that you will have complete or partial coverage :).